Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA)

U Schmidt-Erfurth, V Chong, A Loewenstein… - British Journal of …, 2014 - bjo.bmj.com
Age-related macular degeneration (AMD) is still referred to as the leading cause of severe
and irreversible visual loss world-wide. The disease has a profound effect on quality of life of …

[HTML][HTML] Systemic and ocular fluid compounds as potential biomarkers in age-related macular degeneration

E Kersten, CC Paun, RL Schellevis, CB Hoyng… - survey of …, 2018 - Elsevier
Biomarkers can help unravel mechanisms of disease and identify new targets for therapy.
They can also be useful in clinical practice for monitoring disease progression, evaluation of …

Systemic pharmacokinetics and pharmacodynamics of intravitreal aflibercept, bevacizumab, and ranibizumab

RL Avery, AA Castellarin, NC Steinle, DS Dhoot… - Retina, 2017 - journals.lww.com
Purpose: To evaluate the systemic pharmacokinetics (PKs) of aflibercept, bevacizumab, and
ranibizumab in patients with neovascular age-related macular degeneration (AMD), diabetic …

Neurodevelopmental outcomes following bevacizumab injections for retinopathy of prematurity

J Morin, TM Luu, R Superstein, LH Ospina… - …, 2016 - publications.aap.org
METHODS: Data from the Canadian Neonatal Network and the Canadian Neonatal Follow-
Up Network databases were retrospectively reviewed. Infants born at< 29 weeks' in 2010 …

Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD

RL Avery, AA Castellarin, NC Steinle… - British Journal of …, 2014 - bjo.bmj.com
Background Data comparing systemic exposure and systemic vascular endothelial growth
factor (VEGF) suppression of ranibizumab, bevacizumab and aflibercept following …

Pharmacokinetics of bevacizumab and its effects on serum VEGF and IGF-1 in infants with retinopathy of prematurity

L Kong, AR Bhatt, AB Demny, DK Coats… - … & visual science, 2015 - iovs.arvojournals.org
Purpose.: To measure serum levels of bevacizumab and to compare serum levels of free
vascular endothelial growth factor (VEGF) and insulin-like growth factor-1 (IGF-1) in infants …

Intravitreal anti-vascular endothelial growth factor treatment for retinopathy of prematurity: comparison between Ranibizumab and Bevacizumab

SN Chen, I Lian, YC Hwang, YH Chen, YC Chang… - Retina, 2015 - journals.lww.com
Purpose: To compare the effect and the treatment outcomes of bevacizumab and
ranibizumab in the treatment of Type 1 retinopathy of prematurity (ROP). Methods: This was …

Serum vascular endothelial growth factor after bevacizumab or ranibizumab treatment for retinopathy of prematurity

WC Wu, CP Shih, R Lien, NK Wang, YP Chen… - Retina, 2017 - journals.lww.com
Purpose: To investigate vascular endothelial growth factor (VEGF) levels in the systemic
circulation after intravitreal injections of bevacizumab (IVB) or ranibizumab (IVR) in patients …

Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related …

C Zehetner, R Kirchmair, S Huber… - British Journal of …, 2013 - bjo.bmj.com
Aims To determine the level of vascular endothelial growth factor (VEGF) in the plasma of
patients with diabetic macular edema (DME) and of patients with exudative age-related …

Comparison of intravitreal injection of ranibizumab versus laser therapy for zone II treatment-requiring retinopathy of prematurity

G Zhang, M Yang, J Zeng, G Vakros, K Su, M Chen… - Retina, 2017 - journals.lww.com
Purpose: To compare the efficacy of intravitreal injection of ranibizumab (IVR) monotherapy
and laser therapy for treatment-requiring retinopathy of prematurity (ROP) in Zone II …